ASPEN Lipid Injectable Emulsion Safety Recommendations, Part 1: Background and Adult Considerations.

Autor: Mirtallo JM; The American Society for Parenteral and Enteral Nutrition, Silver Spring, Maryland, USA.; College of Pharmacy, The Ohio State University, Columbus, Ohio, USA., Ayers P; Clinical Pharmacy Services, Baptist Medical Center, Department of Pharmacy, Jackson, Mississippi, USA., Boullata J; Clinical Nutrition Support Services, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA., Gura KM; Boston Children's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Plogsted S; Retired., Anderson CR; Primary Children's Hospital, Salt Lake City, Utah, USA., Worthington P; Retired., Seres DS; Division of Preventive Medicine and Nutrition, Department of Medicine, Institute of Human Nutrition, Columbia University Medical Center, New York, New York, USA., Nicolai E; Nutrition and Food Services, UNC Healthcare Systems, Chapel Hill, North Carolina, USA., Alsharhan M; King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia., Gutsul L; Central Admixture Pharmacy Services, Warrendale, Pennsylvania, USA., Mason AE; BriovaRx Infusion Services, Columbia, Maryland, USA.
Jazyk: angličtina
Zdroj: Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition [Nutr Clin Pract] 2020 Oct; Vol. 35 (5), pp. 769-782. Date of Electronic Publication: 2020 May 27.
DOI: 10.1002/ncp.10496
Abstrakt: Lipid injectable emulsions (ILEs) are complex pharmaceutical formulations used as a source of energy and essential fatty acids in parenteral nutrition. Issues associated with ILE use are distinctly different from oral fat and arise from emulsion stability, dose, and infusion tolerance. Since 1975, soybean oil has been the consistent source oil used in ILE formulations in the US. Partly because of safety concerns with the soybean-based ILE and frequent and long-standing problems with product inventory shortages, new ILE products have become available. Gaps in ILE best practices create a risk for ILE safety errors in prescribing, compounding, and administration of these products. This paper provides information on appropriate indications, dosing, and methods to avoid potential errors with ILE products in the US. This paper (Part 1) will focus on ILE background, information, and recommendations for adult patients, whereas Part 2 of this series will focus on neonatal and pediatric patient-specific information.
(© 2020 American Society for Parenteral and Enteral Nutrition.)
Databáze: MEDLINE
Externí odkaz: